Zymosan A

Zymosan A-induced peritonitis

Peritonitis was induced by i.p. administration of zymosan A (100 mg·kg−1) as described previously. For the measurement of plasma leakage, mice were administered, i.v. or i.p., 100 µL of lipid, dissolved in phosphate-buffered saline (PBS), 30 min prior to i.p. administration (100 mg·kg−1) of zymosan A, and 100 µL of 0.5% Evans blue dye, dissolved in PBS, was injected i.v. just prior to zymosan A injection. Sixty minutes later, unless indicated otherwise, mice were killed by isoflurane inhalation, and peritoneal lavage was performed with 3 mL of ice-cold PBS. Then cells were centrifuged out of the lavage fluid. Finally, Evans blue dye extravasation was determined by measuring the absorbance of supernatants at 610 nm .

To evaluate the effect of the 15-LOX inhibitor (PD146176) on the anti-inflammatory action of 1-(15-HPEPE)-lysoPC, 1-(15-HPEPE)-lysoPC and PD146176 (100 mg·kg−1), dissolved in PBS , were simultaneously administered to mice 30 min prior to i.p. administration of zymosan A, and the plasma leakage was assessed as described above. Separately, in order to measure leucocyte infiltration, lipids were administered 30 min prior to i.p. administration of zymosan A, and 120 min after zymosan A injection, peritoneal lavage was taken, and the total number of cells in the lavage fluid was enumerated by using light microscopy employing tryphan blue staining. Separately, the presence of neutrophils in lavage was determined through the detection of myeloperoxidase (MPO) activity in the lysis buffer, prepared from sonication of cell pellet suspensions (0.5 mL) at 4°C for 5 min, using an MPO chlorination assay kit. One unit is defined as the amount of enzyme that will cause the formation of 1 pmol of fluorescent product min−1 at 25°C.

Case Study 1-Zymosan-A promotes the regeneration of intestinal stem cells by upregulating ASCL2

This study found that Zymosan-A is a substance that can promote the regeneration of intestinal stem cells. Research has shown that Zymosan-A can promote intestinal stem cell regeneration by upregulating the expression of ASCL2 gene. ASCL2 is an important transcription factor that plays a crucial role in the self-renewal and differentiation of intestinal stem cells.

In the experiment, researchers found that the regeneration rate of intestinal stem cells was significantly improved after treatment with Zymosan-A. Further molecular mechanism studies have shown that Zymosan-A can activate the expression of ASCL2 gene, thereby promoting the regeneration of intestinal stem cells. The upregulation of ASCL2 leads to increased proliferation and self-renewal of intestinal stem cells, accelerating the process of intestinal repair and regeneration. The results of this study have significant clinical implications. Intestinal injury and disease are often accompanied by damage and dysfunction of intestinal stem cells, leading to impaired intestinal regeneration. Therefore, utilizing Zymosan-A to promote the regeneration of intestinal stem cells may become a potential therapeutic strategy. By activating the ASCL2 gene, the number and function of intestinal stem cells can be increased, accelerating the repair process of the intestine, which is expected to provide new ideas and methods for the treatment of intestinal injuries and diseases.

In summary, Zymosan-A can promote the regeneration of intestinal stem cells by upregulating the expression of ASCL2 gene, which has potential clinical application prospects. Future research can further explore the mechanism of action of Zymosan-A in intestinal regeneration, providing more theoretical basis for the development of more effective treatments for intestinal injury and diseases.

Case Study 2-Zymosan A Improved Doxorubicin‐Induced Ventricular Remodeling by Evoking Heightened Cardiac Inflammatory Responses and Healing in Mice

This article investigates the role of Zymosan A in improving Doxorubicin induced ventricular remodeling. Doxorubicin is a commonly used chemotherapy drug, but its side effects often lead to heart damage, which in turn causes ventricular remodeling and decreased heart function. Research has shown that Zymosan A, as a β-glucan, can activate the immune system, enhance the inflammatory response and healing process of the heart.

The experimental results showed that administration of Zymosan A to mice significantly improved the cardiac dysfunction and structural changes induced by doxorubicin. Specifically, Zymosan A enhances the activity of macrophages in the heart, promotes the release of inflammatory factors, and thereby stimulates the repair mechanism of the heart. In addition, histological analysis revealed that the Zymosan A treatment group significantly reduced the degree of cardiac fibrosis and increased the survival rate of myocardial cells in mice.

Further mechanistic studies revealed that Zymosan A enhances the immune response of the heart by activating the TLR (Toll like receptor) signaling pathway. This enhanced immune response helps to clear damaged cells and promote the regeneration process, thereby reducing the degree of ventricular remodeling.

In summary, Zymosan A not only improves heart damage caused by doxorubicin, but also provides support for heart repair by inducing stronger cardiac inflammatory responses and healing mechanisms. This discovery provides new ideas for addressing the cardiac toxicity of doxorubicin in clinical practice and suggests that moderate inflammatory response may be beneficial in the treatment of heart injury. Future research can further explore the potential applications of Zymosan A in the treatment of other heart diseases.

Zymosan A is a natural product containing β-1,3-glucan and β-1,6-glucan, widely used in the study of immune system activation and inflammatory response.

Immunological research: Zymosan A can activate macrophages, prompting them to release inflammatory mediators such as cytokines and chemokines, thereby triggering an inflammatory response. Zymosan A can induce activation and proliferation of various immune cells, such as monocytes and dendritic cells, thereby enhancing immune response. Zymosan A can trigger signaling pathways by activating Toll like receptors (TLR)2 and TLR6, thereby activating immune cells and triggering inflammatory responses. Zymosan A can simulate fungal infections and trigger inflammation by activating the host's immune response. Researchers can use Zymosan A to induce inflammatory mediators such as interleukin in mice or cell lines, in order to study the activation mechanism and signaling pathways of immune cells.

Promoting anti-inflammatory therapy research: Zymosan A activates receptors such as Toll like receptors (TLRs) to stimulate inflammatory cells (such as macrophages, dendritic cells, etc.) to release inflammatory mediators such as interleukin-1 (IL-1), tumor necrosis factor alpha (TNF - α), etc., thereby triggering an inflammatory response. These inflammatory mediators can attract more immune cells to the site of inflammation, exacerbating the inflammatory response. In addition, Zymosan A can also activate inflammation related signaling pathways, such as the NF -κB signaling pathway, thereby promoting the activation of inflammatory cells and the production of inflammatory mediators. These processes help to eliminate pathogens and damage tissues, but excessive inflammatory reactions may also lead to the occurrence of inflammatory diseases. Zymosan A can be used to study the pathogenesis and treatment methods of inflammation related diseases.

Antifungal drug screening: Zymosan A can simulate the immune response of fungal infections, promote macrophage phagocytosis and inflammatory response, and help explore the immune system’s response mechanism to fungi. Researchers can use Zymosan A to evaluate the antibacterial efficacy of potential antifungal drugs. By evaluating the effect of drugs on Zymosan A-induced inflammatory response, compounds with antifungal activity can be screened.

• Show All
• Q&As (0)
• Reviews (0)